Continued Concern: Human Subject Protection, the Irb, and Continuing Review
59 Pages Posted: 15 May 2001
Abstract
On September 17, 1999, Jesse Gelsinger, an eighteen-year-old man with a rare metabolic disease, died while undergoing experimental genetic therapy administered in a clinical trial at the University of Pennsylvania. Jesse Gelsinger's death focused public attention on the problem of effective monitoring of clinical trials, otherwise known as continuing review.
In recent years several major government reports have been highly critical of contemporary research oversight. In addition, the Department of Health and Human Services' Office for Human Research Protection has found it necessary to suspend research at a growing number of institutions due to regulatory violations, including failure to conduct appropriate continuing reviews.
Providing adequate protection to all research participants through effective continuing review of clinical trials is a challenging and onerous task, but also an extremely important one. Many believe that limited resources, inadequate personnel, and significant time constraints currently prevent IRBs from performing thorough and effective continuing reviews. Thus far, however, there has been minimal evaluation of mechanisms by which IRB functioning in the area of continuing reviews could be improved.
This article provides a rigorous analysis of the problem of continuing review and suggests a variety of means by which to enhance the review process. The article describes the current oversight system for clinical research under the federal regulations and assesses its deficiencies. It further discusses the importance of the continuing review process in light of relevant ethical principles, economic incentives, and liability concerns. Finally, the author offers a series of recommendations relating to the staffing of IRBs, funding for IRBs, the content of continuing reviews, and other aspects of IRB monitoring operations.
Keywords: Clinical research, Institutional Review Board, continuing review of clinical studies, FDA, HHS, research regulation
JEL Classification: I18
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
The Challenge of Developing Oversight Approaches to Nanobiotechnology
By Jordan Paradise, Susan M. Wolf, ...
-
The Challenge of Developing Oversight Approaches to Nanobiotechnology
-
Developing Oversight Frameworks for Nanobiotechnology
By Jordan Paradise, Susan M. Wolf, ...
-
Stakeholder Participation in New Governance: Lessons from Chicago's Public Housing Reform Experiment
-
Unpackaging Synthetic Biology: Identification of Policy Problems and Options
By Jennifer Kuzma and Todd Tanji
-
Dynamic Governance: Embedding Culture, Capabilities and Change in Singapore
By Boon Siong Neo and Geraldine Chen
-
Gene Therapy Oversight: Lessons for Nanobiotechnology
By Susan M. Wolf, Rishi Gupta, ...
-
Researching Safety and Cost-Effectiveness in the Life Cycle of Nanomedicine
By Thomas Alured Faunce and Kathy Shats